---
title: "J&J’s Tremfya retakes ad spending top spot in June"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292314821.md"
description: "Johnson & Johnson's Tremfya regained the top spot in pharmaceutical ad spending for June with $36.6 million, surpassing AbbVie's Skyrizi ($23.3 million). While overall spend decreased month-over-month for most top drugs, Tremfya maintained its lead. Eli Lilly's Zepbound and J&J's Caplyta held fourth and fifth places respectively. Additionally, GSK's Haleon led in World Cup ad airings."
datetime: "2026-07-10T11:28:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292314821.md)
  - [en](https://longbridge.com/en/news/292314821.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292314821.md)
generator: "portal-rs"
---

# J&J’s Tremfya retakes ad spending top spot in June

After several months of AbbVie leading pharma’s monthly ad spend, Johnson & Johnson is back as Tremfya topped June’s rankings.

J&J’s immunology drug saw spend slightly down by $2.2 million over May, but this was still enough to regain the lead from AbbVie’s rival med Skyrizi, according to data from iSpot.TV. 

AbbVie’s spend dropped like a stone in June for Skyrizi, down from $38.9 million in May to just $23.3 million last month. 

AbbVie’s second blockbuster immunology med Rinvoq took its usual third place, with spend also seeing a big fall, down $7.5 million month over month. 

Eli Lilly’s obesity drug Zepbound came in fourth, just as it did in May, while J&J was back again in fifth place with its atypical antipsychotic drug Caplyta. 

Lundbeck and Otsuka’s neurology drug Rexulti moved up one spot to sixth position. And AbbVie’s Botox made an unusual appearance in seventh place, having not been listed last month or for much of the past year. 

Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease drug Jardiance took its accustomed eighth place, with spend hitting $9.9 million, down from $13.4 million in May. 

The final two places in the top 10 are drugs not listed last month. The spots includes GSK’s respiratory therapy Trelegy and ViiV Healthcare’s long-acting HIV treatment Cabenuva.

Fierce also asked iSpot.TV for a rundown of the pharma companies that have aired ads during English-language FIFA World Cup matches from the start of the tournament through Sunday July 7. 

There has been a real dearth of pharma ads during this period as, according to iSpot.TV, there are few overall ad breaks (given it is live sports) and “most of them go to sponsors." 

GSK’s consumer spin off Haleon took the top billing with the most airings in this period (44), with J&J taking second place with Tremfya for psoriatic arthritis at 13 airings. Haleon’s top position is no surprise given that the company has several marketing tie-ups with the World Cup. 

Lilly’s new obesity pill Foundayo, meanwhile, took the third World Cup spot with seven airings. 

A full list of June’s biggest ad spenders as compiled by iSpot.TV are below. 

**1\. Tremfya** 

**Movement:** Up one spot

**What is it?** J&J’s immunology drug 

**Est. national linear TV ad spend:** $36.6 million (down from $38.8 million in May)

-   UC/Crohn’s disease: $16.4 million
-   Psoriasis: $2 million
-   Psoriatic Arthritis: $18.2 million

**Top TV network by spend share of voice (SOV)**: ABC (18.40%)

**Top TV program by spend SOV:** FIFA World Cup 2026 (10.56%)

**Number of spots:** Six (three psoriatic arthritis, two psoriasis, one UC/Crohn’s disease) 

**Biggest-ticket ad:** “A Million Miles Away: Travels” (est. $16.7 million)

**2\. Skyrizi** 

**Movement:** Down one spot

**What is it?** AbbVie’s immunology drug 

**Est. national linear TV ad spend:** $23.3 million (down from $38.9 million in May)

-   UC/Crohn’s disease: $13.2 million
-   Psoriasis: $7.9 million
-   Psoriatic arthritis: $2.2 million

**Top TV network by spend SOV**: ABC (14.57%)

**Top TV program by spend SOV:** America’s Got Talent (2.67%)

**Number of spots:** Five (one psoriatic arthritis, two psoriasis, two UC/Crohn’s disease) 

**Biggest-ticket ad:** “In the Picture: Tailgate and Mini Golf” (est. $6.7 million)

**3\. Rinvoq** 

**Movement:** No change

**What is it?** AbbVie’s JAK immunology drug

**Est. national linear TV ad spend:** $22.1 million (down from $29.6 million in May)

-   Arthritis: $9 million
-   Eczema: $7 million
-   UC/Crohn’s: $6.2 million

**Top TV network by spend SOV**: ABC (18.21%)

**Top TV program by spend SOV:** America’s Got Talent (3.41%) 

**Number of spots:** Four (one arthritis, one UC/Crohn’s disease, two eczema)

**Biggest-ticket ad:** “Another Day” (est. $9 million)

**4\. Zepbound** 

**Movement:** No change

**What is it?** Eli Lilly’s obesity drug

**Est. national linear TV ad spend:** $18.8 million (down from $22.7 million in May)

**Top TV network by spend SOV**: ABC (33.31%)

**Top TV program by spend SOV:** NBA (16.82%)

**Number of spots:** Nine 

**Biggest-ticket ad:** “Watch This: Data” (est. $4.6 million)

**5\. Caplyta** 

**Movement:** No change

**What is it?** Johnson & Johnson’s atypical antipsychotic drug

**Est. national linear TV ad spend:** $16.4 million (down from $19 million in May)

-   Bipolar depression: $2.5 million
-   MDD: $13.9 million

**Top TV network by spend SOV**: Fox (10.63%)

**Top TV program by spend SOV:** Copa Mundial de la FIFA 2026 (11.76%) 

**Number of spots:** Four (three MDD, one bipolar)

**Biggest-ticket ad:** “Let in the Lyte: Greater Relief” (est. $5.6 million)

**6\. Rexulti (depression)**

**Movement:** Up one spot

**What is it?** Lundbeck and Otsuka’s neurology drug

**Est. national linear TV ad spend:** $15.3 million (up from $14.2 million in May)

**Top TV network by spend SOV**: CBS (11.76%)

**Top TV program by spend SOV:** NCIS (3.57%)

**Number of spots:** One

**Biggest-ticket ad:** “Progress” (est. $15.3 million)

**7\. Botox**

**Movement:** Not listed last month

**What is it?** AbbVie’s injection for aesthetic and therapeutic conditions

**Est. national linear TV ad spend:** $10.8 million (up from $7.4 million in May)

-   Migraine: $5.9 million
-   Cosmetic: $4.9 million

**Top TV network by spend SOV**: CBS (9.03%)

**Top TV program by spend SOV:** Forensic Files (2.99%) 

**Number of spots:** Six (four cosmetic, two migraine)

**Biggest-ticket ad:** “Spectator” (est. $5.4 million)

**8\. Jardiance**

**Movement:** No change

**What is it?** Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease drug

**Est. national linear TV ad spend:** $9.9 million (down from $13.4 million in May)

-   CKD: $3.5 million
-   Diabetes: $6.5 million

**Top TV network by spend SOV**: ABC (16.75%)

**Top TV program by spend SOV:** NBA (9.19%)

**Number of spots:** Three (two CKD, one diabetes)

**Biggest-ticket ad:** “Behind the Scenes” (est. $6.5 million)

**9\. Trelegy**

**Movement:** Not listed last month

**What is it?** GSK’s respiratory therapy 

**Est. national linear TV ad spend:** $8.7 million (up from $5.2 million in May)

**Top TV network by spend SOV**: ABC (22.11%)

**Top TV program by spend SOV:** ABC World News Tonight With David Muir (9.90%)

**Number of spots:** Two

**Biggest-ticket ad:** “An Ugly Reality” (est. $4.7 million)

**10\. Cabenuva**

**Movement:** Not listed last month

**What is it?** ViiV Healthcare’s long-acting HIV treatment

**Est. national linear TV ad spend:** $8.6 million (up from $6.3 million in May)

**Top TV network by spend SOV**: Telemundo (33.83%)

**Top TV program by spend SOV:** Copa Mundial de la FIFA 2026 (33.32%)

**Number of spots:** Four

**Biggest-ticket ad:** “Playa” (est. $3.5 million)

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [HLN.US](https://longbridge.com/en/quote/HLN.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [4578.JP](https://longbridge.com/en/quote/4578.JP.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [Eli Lilly and Company $LLY Shares Purchased by Integrated Wealth Concepts LLC](https://longbridge.com/en/news/298698438.md)
- [Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs](https://longbridge.com/en/news/297082109.md)
- [Saudi Central Bank Has $31.16 Million Stock Holdings in AbbVie Inc. $ABBV](https://longbridge.com/en/news/298802740.md)
- [AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference](https://longbridge.com/en/news/298481438.md)
- [NEOS Investment Management LLC Buys 38,043 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/298824702.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**